Novartis v. Noratech: Federal Circuit Vacates Sacubitril/Valsartan Patent Judgment

In a consequential development for pharmaceutical patent litigation, the U.S. Court of Appeals for the Federal Circuit vacated the district court’s judgment in Novartis AG v. Nanjing Noratech Pharmaceutical Co., Ltd. (Case No. 23-2317), remanding the matter for further proceedings following a pivotal ruling in a related appeal. The outcome, finalized on March 11, 2025, centers on two patents protecting sacubitril/valsartan — the active combination in Novartis’s blockbuster heart failure drug Entresto® — and directly affects Noratech’s ability to launch a generic version in the U.S. market.

This case illustrates the increasingly complex, multi-front nature of branded pharmaceutical patent enforcement, where the fate of one infringement action can hinge entirely on the validity determination in a parallel proceeding. For patent attorneys, in-house IP counsel, and R&D teams operating in the pharmaceutical space, this litigation offers critical lessons on coordinated appellate strategy, the interdependence of related patent cases, and the durable importance of compound patent portfolios in protecting high-value drug franchises.

Case Overview

The Parties

The Patents at Issue

Two U.S. patents were central to this dispute, protecting the sacubitril/valsartan combination:

• • U.S. Patent No. 8,101,659 B2 — Covers composition and formulation aspects of the sacubitril/valsartan combination.
• • U.S. Patent No. 11,058,667 B2 — A later-issued patent with claims directed to sacubitril/valsartan formulations and potentially therapeutic methods.

Both patents protect a novel supramolecular complex combining an angiotensin receptor blocker (valsartan) and a neprilysin inhibitor (sacubitril), representing a distinct pharmacological innovation in heart failure treatment.

Legal Representation

Novartis was represented by Morrison & Foerster LLP and Venable LLP, with counsel including Christina A. L. Schwarz, Deanne Maynard, Nicholas Kallas, and Seth W. Lloyd.

Noratech was represented by Husch Blackwell LLP, with Donald J. Mizerk and Matthew Kamps as lead counsel.

Litigation Timeline & Procedural History

The case was filed on August 23, 2023, in the District of Columbia Circuit, with the appeal docketed before the U.S. Court of Appeals for the Federal Circuit. The matter closed on March 11, 2025, after a duration of 566 days — approximately 18 months from filing to appellate resolution.

Critically, this appeal did not proceed in isolation. It ran concurrently with Appeal No. 2023-2218 and a related matter, Appeal No. 2023-2319, involving what appears to be a parallel ANDA challenge to the same Novartis patents. The Federal Circuit’s disposition of the validity question in Appeal No. 2023-2218 became the dispositive event driving the outcome here.

A key procedural milestone was Noratech’s motion to stay the final judgment pending appeal and Novartis’s motion to dismiss — both ultimately overtaken when the court addressed the interconnected validity ruling. The parties’ joint statement acknowledging that the judgment in this case should be vacated if the invalidity ruling in 2023-2218 was not affirmed reflects sophisticated multi-case coordination and appellate awareness from both sides.

The Verdict & Legal Analysis

Outcome

The Federal Circuit issued an order vacating the district court’s judgment and remanding the case for further proceedings. Simultaneously, the court stayed the district court’s judgment pending issuance of mandate in Appeal Nos. 2023-2317 and 2023-2319. No damages were awarded, and each party was ordered to bear its own costs. An injunction was entered in the related Appeal No. 2023-2218 preventing defendants in that case from launching their generic drug until mandate issues.

Verdict Cause Analysis

The outcome in this case was not driven by a merits-based infringement determination on the ‘659 or ‘667 patents. Instead, it was procedurally contingent on the Federal Circuit’s decision in Appeal No. 2023-2218, where the court reversed the invalidity judgment against Novartis’s patents. Because the parties had jointly agreed that a non-affirmance of invalidity would necessitate vacatur and remand here, the Federal Circuit gave effect to that stipulation.

This procedural architecture is notable: the district court had apparently rendered a judgment — likely unfavorable to Novartis on one or more grounds — that was dependent on the validity finding subsequently reversed at the appellate level. The reversal of invalidity in the companion case restored the legal foundation for Novartis’s infringement claims, making it necessary to return the case to the district court to adjudicate infringement on a now-valid patent basis.

Legal Significance

This case reinforces a critical but underappreciated principle in multi-defendant Hatch-Waxman litigation: validity rulings in one case can structurally determine outcomes in parallel cases involving the same patents. The Federal Circuit’s willingness to vacate and remand based on a companion appeal ruling — without conducting an independent merits review — reflects the court’s pragmatic approach to related ANDA cases.

The injunctive posture is equally significant. By enjoining generic launch in Appeal No. 2023-2218 pending mandate, the Federal Circuit effectively preserved Novartis’s market exclusivity across all related defendants during the pendency of appellate proceedings, demonstrating the continued potency of patent-based exclusionary rights in the pharmaceutical context.

Strategic Takeaways

For Patent Holders: Coordinating multi-defendant ANDA litigation through parallel filings and joint appellate strategies can create structural leverage. A validity victory in one proceeding can cascade favorably across related cases when properly stipulated.

For Accused Infringers: Joint stipulations regarding case interdependence — while pragmatically efficient — can create vulnerability if the foundational invalidity argument fails on appeal. Defense teams should carefully evaluate whether such stipulations are strategically optimal.

For R&D Teams: The durability of Novartis’s sacubitril/valsartan patent portfolio through multiple ANDA challenges underscores the importance of layered patent protection covering both composition and formulation aspects of novel drug compounds.

Industry & Competitive Implications

The Novartis-Noratech outcome contributes to a broader pattern of aggressive Entresto® patent enforcement by Novartis against multiple generic entrants. With Entresto® generating over $5 billion in annual global sales, each successful ANDA challenge represents a multi-billion-dollar commercial threat — justifying extensive, coordinated litigation resources.

For the generic pharmaceutical industry, the Federal Circuit’s reversal of invalidity in the companion appeal signals continued judicial deference to innovative compound patents when challenged on obviousness or related grounds. Generic manufacturers pursuing sacubitril/valsartan ANDA approvals should anticipate robust opposition and carefully evaluate non-infringement design-around strategies rather than relying solely on invalidity arguments.

The case also highlights the growing role of multi-case appellate coordination as a litigation strategy in complex Hatch-Waxman disputes. Branded pharmaceutical companies increasingly structure their enforcement campaigns to create interdependencies between related proceedings, maximizing the strategic impact of favorable appellate rulings.

From a licensing perspective, the outcome reinforces Novartis’s negotiating position in any future settlement discussions with generic entrants, as the patent validity foundation has now survived Federal Circuit scrutiny.

❓ Frequently Asked Questions (FAQ)

What patents were involved in Novartis v. Nanjing Noratech?

U.S. Patent Nos. 8,101,659 B2 and 11,058,667 B2, covering sacubitril/valsartan formulations marketed as Entresto®.

Why was the district court judgment vacated?

The Federal Circuit reversed the invalidity ruling in the companion Appeal No. 2023-2218, triggering the parties’ joint stipulation that vacatur and remand were appropriate in this case.

How does this affect sacubitril/valsartan generic patent litigation broadly?

The reversal of invalidity strengthens Novartis’s enforcement position against all pending generic challengers, likely delaying generic market entry.

🔗 Resources: USPTO Patent Center | Federal Circuit Opinions | PACER Case Lookup